ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia

por Tatiana E. Bialik, Vladimir I. Vorob'ev, Valerii A. Ionin, Loic Ysebaert, Kamil D. Kaplanov, Larisa P. Mendeleeva, Evgenii A. Nikitin, Vadim V. Ptushkin, Olga S. Samoilova, Elena A. Stadnik
Publicado 2021

ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution

por Irina V. Poddubnaya, Lyubov S. Al-Radi, Tatyana E. Byalik, Kamil D. Kaplanov, Valentina Z. Molostvova, Evgeniy A. Nikitin, Tatyana I. Pospelova, Vadim V. Ptushkin, Olga S. Samoilova, Elena A. Stadnik, Gayane S. Tumyan
Publicado 2020